ID	DDInter2028
	Drug Type	biotech
	Protein Chemical Formula	None
	Protein Average Weight	148000.000
	CAS Number	1326232-46-5
	Description	Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.[A237074,L34929] The standard therapy for systemic lupus erythematosus consists of antimalarials like [hydroxychloroquine], glucocorticoids like [dexamethasone], and disease modifying antirheumatic drugs like [methotrexate].[A237079,L34929] Three monoclonal antibodies (anifrolumab, [rontalizumab], and [sifalimumab]) that target the type 1 interferon pathway entered clinical trials as potential treatments for systemic lupus erythematosus, but so far only anifrolumab has been approved.[A237054] The design of early clinical trials of anti-interferon treatments such as anifrolumab, rontalizumab, and sifalimumab have come under criticism.[A237054] The design of the clinical trials use different definitions of autoantibody positivity, making comparison between trials difficult; all trials involve large portions of patients also using corticosteroids, which may alter patient responses in the experimental and placebo groups; and patient populations were largely homogenous, which may have increased the odds of success of the trial.[A237054] Anifrolumab has also been investigated for the treatment of Scleroderma.[A237044] Anifrolumab was granted FDA approval on 30 July 2021.[L34929]
	ATC Classification	L04AA51
Sequences	None
Useful Links	DrugBank PubChem Substance Wikipedia